Olema Oncology to Participate in Upcoming Investor Conferences in June
Olema Oncology, a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, announced its participation in two upcoming investor conferences in June 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olema Oncology, a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for women's cancers, announced its participation in two upcoming investor conferences in June 2024. The management team will join the Jefferies Global Healthcare Conference on June 5 at 2:00 p.m. ET in New York and the Goldman Sachs 45th Annual Global Healthcare Conference on June 12 at 11:20 a.m. ET in Miami. Both presentations will be in a fireside chat format. Live webcasts of these sessions will be available on Olema's investor relations website and archived for 30 days.
Positive
- Participation in Jefferies Global Healthcare Conference may raise investor awareness.
- Inclusion in Goldman Sachs 45th Annual Global Healthcare Conference could attract potential investors.
- Availability of live webcasts broadens access to the presentations and may boost investor confidence.
Negative
- No new clinical data or financial updates were announced, potentially leaving investors seeking more substantial news.
- The PR doesn’t address any advancements or milestones in their targeted therapies for women's cancers, which might concern investors looking for progress.
Details
News Market Reaction – OLMA
The recorded move for OLMA in the trading session of this news was +2.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
Date: Wednesday, June 5, 2024, at 2:00 p.m. ET
Location: Marriott Marquis in New York, NY
Format: Fireside Chat
Goldman Sachs 45th Annual Global Healthcare Conference
Date: Wednesday, June 12, 2024, at 11:20 a.m. ET
Location: Loews Miami Beach Hotel in Miami, FL
Format: Fireside Chat
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.